FAITAVI - Major Late-Breaking Trial from EuroPCR 2025

Stephan Windecker and Flavio Ribichini review the outcomes of the FAITAVI trial, presented during the #europcr 2025 LBT session.

As coronary artery disease is the most common cardiac comorbidity in patients undergoing TAVI, the trial set out to evaluate whether physiology-guided decision-making could offer better clarity.

When performing diagnostic angiography before TAVI, clinicians often find intermediate coronary lesions that don’t obviously require revascularisation — so what's the right strategy in these cases?

FAITAVI is the first randomised trial comparing angiography-guided versus FFR-guided PCI decisions in the TAVI setting. Learn more about the study design, inspired by FAME-1, and how the results support the feasibility and value of FFR measurements in patients with CAD undergoing TAVI. The data also confirm that intermediate lesions can safely be left untreated.

Listen to this episode now to understand how these findings could change practice!

Hosted on Acast. See acast.com/privacy for more information.